MSN is lined up to copy 6 of the blockbuster drugs on this tracker, which earned $27.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | MSN's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Jul 2025 | $7.7B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Sep 2026 | $2.7B |
| Cabometyx | Exelixis | Generic | 2031 | Tentative approval; lost patent trial (2023) | $2.1B |
| Jakafi | Incyte | Generic | 2028 | In litigation | $3.1B |
| Calquence | AstraZeneca | Generic | 2032 | Settled Dec 2025, terms confidential | $3.5B |
Company facts: ZaubaCorp company record. Each drug page lists sources for these entries. Brand sales show the size of the market, not MSN's share of it.